Rennova Health, Inc.
RNVA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $18,686 | $13,036 | $3,224 | $7,200 |
| % Growth | 43.3% | 304.4% | -55.2% | – |
| Cost of Goods Sold | $7,575 | $6,768 | $5,292 | $11,784 |
| Gross Profit | $11,111 | $6,268 | -$2,069 | -$4,583 |
| % Margin | 59.5% | 48.1% | -64.2% | -63.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $9,435 | $7,217 | $7,508 | $11,661 |
| SG&A Expenses | $9,435 | $7,217 | $7,508 | $11,661 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $311 | $460 | $2,944 | $951 |
| Operating Expenses | $9,746 | $7,678 | $10,452 | $12,612 |
| Operating Income | $1,366 | -$1,410 | -$12,521 | -$17,195 |
| % Margin | 7.3% | -10.8% | -388.4% | -238.8% |
| Other Income/Exp. Net | -$1,680 | -$1,628 | $7,428 | -$1,757 |
| Pre-Tax Income | -$314 | -$3,037 | -$5,093 | -$18,952 |
| Tax Expense | $240 | $313 | $180 | -$1,308 |
| Net Income | -$7,729 | -$3,293 | $5,605 | -$18,340 |
| % Margin | -41.4% | -25.3% | 173.9% | -254.7% |
| EPS | -0 | -0.033 | -913.37 | -93,864,830.67 |
| % Growth | 99.4% | 100% | 100% | – |
| EPS Diluted | -0 | -0.033 | -913.37 | -93,864,830.67 |
| Weighted Avg Shares Out | 32,825,520 | 9,992,238 | 548 | 0 |
| Weighted Avg Shares Out Dil | 32,825,520 | 9,992,238 | 548 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,453 | $2,258 | $3,186 | $9,841 |
| Depreciation & Amortization | $311 | $469 | $644 | $701 |
| EBITDA | $1,449 | -$310 | -$1,263 | -$8,410 |
| % Margin | 7.8% | -2.4% | -39.2% | -116.8% |